Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

King offers new dosage strengths of Avinza for chronic pain

Feb. 6, 2009

New mGluR1 and mGluR5 receptor ligands discovered at Gedeon Richter

Feb. 6, 2009

Novel T-type calcium channel inhibitors discovered by Merck & Co. researchers

Feb. 5, 2009

GlaxoSmithKline develops quinoline NK3 receptor antagonists with enhanced CNS activity

Feb. 4, 2009

Corcept reports results from clinical study of Corlux and Risperdal in weight gain

Feb. 4, 2009

Laminin-111 a potential therapy for alpha7 integrin congenital myopathy

Feb. 4, 2009

PTC completes enrollment in pivotal PTC-124 muscular dystrophy trial

Feb. 4, 2009

AstraZeneca scientists present new GABA-A2 receptor agonists with antipsychotic activity

Feb. 4, 2009

AstraZeneca and Astex scientists jointly impart novel BACE inhibitors

Feb. 4, 2009

Safinamide significantly improved motor function in Parkinson's disease

Feb. 3, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...